Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760303 | 0.84 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL5693144 | 0.84 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL17231980 | 0.81 | PPARD (0.47) | SIGMAR1MEN1APAF1GAACASP3 | |
| SCHEMBL17231983 | 0.80 | MC4R (0.63) | SIGMAR1HRH2MC4RMEN1APAF1 | |
| SCHEMBL27951589 | 0.79 | SIGMAR1 (0.43) | SIGMAR1MEN1APAF1GAACASP3 | |
| SCHEMBL24755096 | 0.76 | HDAC1 (0.39) | MEN1KMT2A | |
| SCHEMBL6920302 | 0.74 | HDAC8 (0.53) | SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14012100 | 0.74 | PRCP (0.49) | MEN1KMT2A | |
| SCHEMBL7127952 | 0.73 | SIGMAR1 (0.47) | SIGMAR1HRH2MEN1APAF1GAA | |
| SCHEMBL6920539 | 0.73 | HTR1A (0.50) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | SIGMAR1 1029/4885HRH2 38/4885MC4R 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.